8 ms·

For semaglutide, the newest and most potent GLP1. United States: The main patent is expected to expire around 2032. Monthly Price: $950 - $1,350+ (cash price w

by jtrn 1y ago

For semaglutide, the newest and most potent GLP1. United States: The main patent is expected to expire around 2032. Monthly Price: $950 - $1,350+ (cash price without insurance) Norway: The main patent is expected to expire around 2031. Monthly Price: $109 - $301 (cash price equivalent in USD)

thatnerdyguy 1y ago
I'll note that in the US that 1000+ is the "list price". For those paying out of pocket, both zepbound and wegovy offer coupons available to anyone taking it down to $500 (and I'll note that discounted price keeps coming down, slowly, as well)
glp1guide 1y ago
> For semaglutide, the newest and most potent GLP1. Tirzepatide is the most potent GLP1 https://glp1.guide/content/semaglutide-vs-tirzepatide-clinical-trial/ https://glp1.guide/content/semaglutide-vs-tirzepatide-clinic...
- hippich 1y ago
  Can't find the post on Reddit right now, but someone broke all three down and it is more nuanced. They act slightly differently in different areas. Before I started experiments on "my lab rat" with retatrutide, I found that combination of the about half max dose of semaglutide and 1/3 of Max dose of tirzepatide had the best combination of losing weight and lowering side effects. But another "lab rat" did not respond that well to this combo and we keep adjusting it. Retatrutide so far looks the most compatible, but it is sample of 1.
  - stewarts 1y ago
    I've had pretty good results on Tirz, definitely interested in how Reta will compare.
  - glp1guide 1y ago
    Retatrutide looks to be very effective, but it's not possible to get legally/safely at this point. TONS of experience/knowledge in the r/retatrutide subreddit though, a lot of pretty conscientious consumers in there that have done their research, but obviously impossible to recommend outside of finding a sanctioned study to join. That said, Reta is a triple agonist[0] and it seems to be quite amazing with good muscle retention as well -- it's unclear if this is just the people who are taking it being more likely to be gym goers. Up until now the only formulation I've seen that specifically targets preserving muscle is GLP1s in combination with bimagrumab[1]. [0]: https://glp1.guide/content/a-new-glp1-retatrutide/ https://glp1.guide/content/a-new-glp1-retatrutide/ [1]: https://glp1.guide/content/preserving-muscle-glp1s-with-bimagrumab/ https://glp1.guide/content/preserving-muscle-glp1s-with-bima...
- jtrn 1y ago
  This is where I failed as a psychologist because I don't have extensive training in pharmacodynamics, so I forgot that "potent" is a specific term in that world. What I meant was: I subjectively believe that Semaglutide is the best choice for weight loss, given the overall profile and response in my subjective clinical experience. A fancy way of saying: I *think* Semaglutide is best.
  - glp1guide 1y ago
    Ah -- the linked research trial contains evidence that it is not the best, Tirzepatide is more effective. Unless you mean that Semaglutide worked best for you, right now the research points at Tirzepatide being most effective for weight loss (says nothing about t2d though).
    - jtrn 1y ago
      No, for my patients. Again. Purely subjective and anecdotal.
loeg 1y ago
That US price is way too high. No consumer pays that much. You can buy it straight from Novo for $500/mo.
- noboostforyou 1y ago
  Lilly also offers it direct to consumer for $500/mo
  - loeg 1y ago
    Lilly offers Tirzepatide for that price, yes. GP is explicitly talking about Semaglutide, though.
    - jtrn 1y ago
      Yes.
int_19h 1y ago
If these things really boost life expectancy that much, this sounds like a textbook case for eminent domain.
- eru 1y ago
  I'm no fan of the patent system, but "patent system promises spoils for coming up with great new drug, companies comes up with great new drug, companies gets spoils" is exactly how it's supposed to work. Yes, it's sucks that you have to pay, but that's how you incentives getting the wonder drugs invented in the first place. (I have my own take on this, but if anything this is a 'textbook case' in favour of the patent system.) Eminent domain would still require fair compensation to the company, so you'd have to pay them more or less what they'd lose from not having the patent anymore. (Though I think the term you might be looking for is 'compulsory licensing' or so? Not sure.)
  - LadyCailin 1y ago
    If this research was done fully via the public system in the first place, it would be an easier nut to crack. I mean, some of it is already, and that’s the absolute worst scenario: the public paid for it via taxes, and now has to pay for it privately after the fact.
    - coredog64 1y ago
      The public isn't paying for the phase 2 and phase 3 trials.
  - pmyteh 1y ago
    Depending on how transformative the effects are (and the price drop possible upon genericisation) then there could be a compulsory licensing trade to do here. The drug companies are presumably pricing optimally for profit (but not for maximum public benefit, for which the optimum price is ~0). You could calculate the net present value of the drug companies' total profits attributable to the patent, add on 10% as a bonus, and pay them off. If the welfare gains of having cheap drugs are genuinely greater than the value of the patent to the holder, this would be win/win.
deleted 1y ago
[deleted]
AbstractH24 1y ago
> United States: The main patent is expected to expire around 2032. Monthly Price: $950 - $1,350+ (cash price without insurance) While 2032 seems very far away now, its actually remarkably soon in the grand scheme of society. My understanding is one of their defendable moats is the patent not on the compound itself, but on the injectors. Which is far longer.
- dmoy 1y ago
  > one of their defendable moats is the patent not on the compound itself, but on the injectors. Which is far longer. That is very typical in the drug/medical industry. To the point where it is sometimes (often? usually?) an intentional strategy. https://sites.uclawsf.edu/evergreensearch/ https://sites.uclawsf.edu/evergreensearch/
- thephyber 1y ago
  Yeah, the drug + the injector together are the patentable thing. When the first patent nears expiration, they work on an iteration of the injector or a time release change for the drug, then they get another few decades of product monopoly. They have also made a business of either stifling or “catch and kill”ing of the generics for their products. It’s cheaper to pay off a generic manufacturer to not compete with the new thing than it is to lose price elasticity of the n non-generic.
  - s1artibartfast 1y ago
    This is not correct. New patents cover the new combination, but don't prevent practice of the old combination
    - AbstractH24 1y ago
      Scroll down to the area referencing footnote 9 in this article https://pmc.ncbi.nlm.nih.gov/articles/PMC11457043/ https://pmc.ncbi.nlm.nih.gov/articles/PMC11457043/ That articulates it better than I will
shadowtree 1y ago
Canada: January 2026(!) Novo lawyers messed up, didn't renew the patent filing over a payment dispute. Hilarity is ensuing. https://www.cnbc.com/2025/07/09/hims-hers-generic-semaglutide-novo-nordisk-ozempic-wegovy-canada.html https://www.cnbc.com/2025/07/09/hims-hers-generic-semaglutid... And once generics for GLP-1s are going in Canada, Section 804 of the FD&C act becomes VERY interesting: https://www.fda.gov/about-fda/reports/importation-program-under-section-804-fdc-act https://www.fda.gov/about-fda/reports/importation-program-un... Reimports of generics from Canada into the US here. we. go.
- barumrho 1y ago
  LOL, that must be one of the biggest fuck ups in pharmaceutical industry.
- htrp 1y ago
  All over 250 CAD >Novo Nordisk’s lawyers requested a refund for the paid 2017 maintenance fee of $250 Canadian dollars ($185) because the company wanted more time to see if it wanted to pay it, according to letters included in the documents. >Two years later, the office sent a letter saying the fee, which now included a late charge bringing the total to CA$450, was not received by the prescribed due date. >Novo Nordisk had a one-year grace period to pay, but never did, and so its patent lapsed in Canada. It lapsed in 2020 when the fee was not received, but it doesn’t expire until January.

by jtrn 1y ago

thatnerdyguy 1y ago

I'll note that in the US that 1000+ is the "list price". For those paying out of pocket, both zepbound and wegovy offer coupons available to anyone taking it down to $500 (and I'll note that discounted price keeps coming down, slowly, as well)

glp1guide 1y ago

> For semaglutide, the newest and most potent GLP1. Tirzepatide is the most potent GLP1 https://glp1.guide/content/semaglutide-vs-tirzepatide-clinical-trial/ https://glp1.guide/content/semaglutide-vs-tirzepatide-clinic...

hippich 1y ago
Can't find the post on Reddit right now, but someone broke all three down and it is more nuanced. They act slightly differently in different areas. Before I started experiments on "my lab rat" with retatrutide, I found that combination of the about half max dose of semaglutide and 1/3 of Max dose of tirzepatide had the best combination of losing weight and lowering side effects. But another "lab rat" did not respond that well to this combo and we keep adjusting it. Retatrutide so far looks the most compatible, but it is sample of 1.
- stewarts 1y ago
  I've had pretty good results on Tirz, definitely interested in how Reta will compare.
- glp1guide 1y ago
  Retatrutide looks to be very effective, but it's not possible to get legally/safely at this point. TONS of experience/knowledge in the r/retatrutide subreddit though, a lot of pretty conscientious consumers in there that have done their research, but obviously impossible to recommend outside of finding a sanctioned study to join. That said, Reta is a triple agonist[0] and it seems to be quite amazing with good muscle retention as well -- it's unclear if this is just the people who are taking it being more likely to be gym goers. Up until now the only formulation I've seen that specifically targets preserving muscle is GLP1s in combination with bimagrumab[1]. [0]: https://glp1.guide/content/a-new-glp1-retatrutide/ https://glp1.guide/content/a-new-glp1-retatrutide/ [1]: https://glp1.guide/content/preserving-muscle-glp1s-with-bimagrumab/ https://glp1.guide/content/preserving-muscle-glp1s-with-bima...
jtrn 1y ago
This is where I failed as a psychologist because I don't have extensive training in pharmacodynamics, so I forgot that "potent" is a specific term in that world. What I meant was: I subjectively believe that Semaglutide is the best choice for weight loss, given the overall profile and response in my subjective clinical experience. A fancy way of saying: I *think* Semaglutide is best.
- glp1guide 1y ago
  Ah -- the linked research trial contains evidence that it is not the best, Tirzepatide is more effective. Unless you mean that Semaglutide worked best for you, right now the research points at Tirzepatide being most effective for weight loss (says nothing about t2d though).
  - jtrn 1y ago
    No, for my patients. Again. Purely subjective and anecdotal.

loeg 1y ago

That US price is way too high. No consumer pays that much. You can buy it straight from Novo for $500/mo.

noboostforyou 1y ago
Lilly also offers it direct to consumer for $500/mo
- loeg 1y ago
  Lilly offers Tirzepatide for that price, yes. GP is explicitly talking about Semaglutide, though.
  - jtrn 1y ago
    Yes.

int_19h 1y ago

If these things really boost life expectancy that much, this sounds like a textbook case for eminent domain.

eru 1y ago
I'm no fan of the patent system, but "patent system promises spoils for coming up with great new drug, companies comes up with great new drug, companies gets spoils" is exactly how it's supposed to work. Yes, it's sucks that you have to pay, but that's how you incentives getting the wonder drugs invented in the first place. (I have my own take on this, but if anything this is a 'textbook case' in favour of the patent system.) Eminent domain would still require fair compensation to the company, so you'd have to pay them more or less what they'd lose from not having the patent anymore. (Though I think the term you might be looking for is 'compulsory licensing' or so? Not sure.)
- LadyCailin 1y ago
  If this research was done fully via the public system in the first place, it would be an easier nut to crack. I mean, some of it is already, and that’s the absolute worst scenario: the public paid for it via taxes, and now has to pay for it privately after the fact.
  - coredog64 1y ago
    The public isn't paying for the phase 2 and phase 3 trials.
- pmyteh 1y ago
  Depending on how transformative the effects are (and the price drop possible upon genericisation) then there could be a compulsory licensing trade to do here. The drug companies are presumably pricing optimally for profit (but not for maximum public benefit, for which the optimum price is ~0). You could calculate the net present value of the drug companies' total profits attributable to the patent, add on 10% as a bonus, and pay them off. If the welfare gains of having cheap drugs are genuinely greater than the value of the patent to the holder, this would be win/win.

deleted 1y ago

[deleted]

AbstractH24 1y ago

> United States: The main patent is expected to expire around 2032. Monthly Price: $950 - $1,350+ (cash price without insurance) While 2032 seems very far away now, its actually remarkably soon in the grand scheme of society. My understanding is one of their defendable moats is the patent not on the compound itself, but on the injectors. Which is far longer.

dmoy 1y ago
> one of their defendable moats is the patent not on the compound itself, but on the injectors. Which is far longer. That is very typical in the drug/medical industry. To the point where it is sometimes (often? usually?) an intentional strategy. https://sites.uclawsf.edu/evergreensearch/ https://sites.uclawsf.edu/evergreensearch/
thephyber 1y ago
Yeah, the drug + the injector together are the patentable thing. When the first patent nears expiration, they work on an iteration of the injector or a time release change for the drug, then they get another few decades of product monopoly. They have also made a business of either stifling or “catch and kill”ing of the generics for their products. It’s cheaper to pay off a generic manufacturer to not compete with the new thing than it is to lose price elasticity of the n non-generic.
- s1artibartfast 1y ago
  This is not correct. New patents cover the new combination, but don't prevent practice of the old combination
  - AbstractH24 1y ago
    Scroll down to the area referencing footnote 9 in this article https://pmc.ncbi.nlm.nih.gov/articles/PMC11457043/ https://pmc.ncbi.nlm.nih.gov/articles/PMC11457043/ That articulates it better than I will

shadowtree 1y ago

Canada: January 2026(!) Novo lawyers messed up, didn't renew the patent filing over a payment dispute. Hilarity is ensuing. https://www.cnbc.com/2025/07/09/hims-hers-generic-semaglutide-novo-nordisk-ozempic-wegovy-canada.html https://www.cnbc.com/2025/07/09/hims-hers-generic-semaglutid... And once generics for GLP-1s are going in Canada, Section 804 of the FD&C act becomes VERY interesting: https://www.fda.gov/about-fda/reports/importation-program-under-section-804-fdc-act https://www.fda.gov/about-fda/reports/importation-program-un... Reimports of generics from Canada into the US here. we. go.

barumrho 1y ago
LOL, that must be one of the biggest fuck ups in pharmaceutical industry.
htrp 1y ago
All over 250 CAD >Novo Nordisk’s lawyers requested a refund for the paid 2017 maintenance fee of $250 Canadian dollars ($185) because the company wanted more time to see if it wanted to pay it, according to letters included in the documents. >Two years later, the office sent a letter saying the fee, which now included a late charge bringing the total to CA$450, was not received by the prescribed due date. >Novo Nordisk had a one-year grace period to pay, but never did, and so its patent lapsed in Canada. It lapsed in 2020 when the fee was not received, but it doesn’t expire until January.